Cover Image

Cost-effectiveness analysis of gemtuzumab ozogamicin for the treatment of de novo CD33-positive Acute Myeloid Leukaemia (AML) in Italy

Abstract Background Based on the results from the ALFA-0701 study, gemtuzumab ozogamicin (GO) has been approved by the European Medicine Agency and by the Italian Drug Agency for the first line treatment of de novo acute-myeloid leukemia (AML). In this analysis, we assessed the cost-effectiveness of...

Full description

Saved in:

Bibliographic Details
Main Authors:	Roberto Cairoli (Author), Gianluca Furneri (Author), Roberto Di Virgilio (Author), Barbara Veggia (Author), Felicetto Ferrara (Author)
Format:	Book
Published:	BMC, 2023-01-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Cost-Effectiveness Analysis of Gemtuzumab Ozogamicin for First-Line Treatment of Patients with Cd-33 Positive Acute Myeloid Leukaemia in Spain
by: Mareque M, et al.
Published: (2021)

Cost-Effectiveness Analysis of Gemtuzumab Ozogamicin for First-Line Treatment of Patients with Cd-33 Positive Acute Myeloid Leukaemia in Spain [Corrigendum]
by: Mareque M, et al.
Published: (2021)

Gemtuzumab ozogamicin and novel antibody-drug conjugates in clinical trials for acute myeloid leukemia
by: Bo Yu, et al.
Published: (2019)

The biology of MDR1-P-glycoprotein (MDR1-Pgp) in designing functional antibody drug conjugates (ADCs): the experience of gemtuzumab ozogamicin
by: Maurizio Cianfriglia
Published: (2013)

The Biology and Treatment of Myeloid Leukaemias
by: Ewa Marcinkowska (Ed.)
Published: (2018)

Exploring the acute myeloid leukaemias
by: TB Thapa
Published: (2013)

T-ALL with TEL/AML1 Translocation, Aberrant Expression of CD19 and 33: Case Report and Literature Review
by: Kave Jasseb, et al.
Published: (2016)

New and Emerging Targeted Therapies for Pediatric Acute Myeloid Leukemia (AML)
by: Jing Chen, et al.
Published: (2020)

Extramedullary Myeloid Cell Tumour Presenting As Leukaemia Cutis
by: Thappa Devinder Mohan, et al.
Published: (2002)

Spontaneous chest wall haematoma in chronic myeloid leukaemia
by: Mohamed Dwebi, et al.
Published: (2019)

Cerebral Infectious Opportunistic Lesions in a Patient with Acute Myeloid Leukaemia: The Challenge of Diagnosis and Clinical Management
by: Gabriele Cavazza, et al.
Published: (2024)

Bilateral Inguinal Ulcerations as First Presentation of Acute Myeloid Leukaemia
by: Jana Dorothea Braun, et al.
Published: (2019)

Acute myeloid leukaemia: a paradigm for the clonal evolution of cancer?
by: Carolyn S. Grove, et al.
Published: (2014)

The use of 5-azacytidine in pregnant patient with Acute Myeloid Leukemia (AML): a case report
by: Abdullah M. Alrajhi, et al.
Published: (2019)

Validated Instruments of Quality of Life (QOL) in Patients With Acute Myeloid Leukemia (AML) and Other Cancers
by: Maribel Salas, et al.
Published: (2020)

Pediatric Acute Myeloid Leukemia (AML): From Genes to Models Toward Targeted Therapeutic Intervention
by: Thomas Mercher, et al.
Published: (2019)

Suchilactone inhibits the growth of acute myeloid leukaemia by inactivating SHP2
by: Jingjing Wu, et al.
Published: (2022)

Cerium oxide nanoparticles-assisted aptasensor for chronic myeloid leukaemia detection
by: Yuspian Nur, et al.
Published: (2024)

Targeting MDR1-P-glycoprotein (MDR1-Pgp) in immunochemotherapy of acute myeloid leukemia (AML)
by: Maurizio Cianfriglia
Published: (2013)

Corrigendum: Pediatric Acute Myeloid Leukemia (AML): From Genes to Models Toward Targeted Therapeutic Intervention
by: Thomas Mercher, et al.
Published: (2019)

Molecular characterisation of NPM1 and FLT3-ITD mutations in a central South African adult de novo acute myeloid leukaemia cohort
by: Jean F. Kloppers, et al.
Published: (2021)

A Case of Untreated Myeloid Sarcoma of the Pancreas Head Region: Diagnostic Process of AML Subtyping in an Autoptic Case
by: Yuki Fukumura, et al.
Published: (2021)

Radotinib-induced Eruptive Melanocytic Naevi in a Patient with Chronic Myeloid Leukaemia
by: Jung Min Lee, et al.
Published: (2024)

Discovery of novel and potent CDK8 inhibitors for the treatment of acute myeloid leukaemia
by: Zhuoying Chen, et al.
Published: (2024)

Atypical myeloid neoplasm posing a diagnostic challenge between BPDCN and AML: a case report and review of literature
by: Sabina Hajiyeva, et al.
Published: (2017)

Hyperpigmentation of the hard palate mucosa in a patient with chronic myeloid leukaemia taking imatinib
by: Gian Paolo Bombeccari, et al.
Published: (2017)

Targeting NOX2 and glycolytic metabolism as a therapeutic strategy in acute myeloid leukaemia
by: Carla Ijurko, et al.
Published: (2024)

Inotuzumab ozogamicin in clinical development for acute lymphoblastic leukemia and non-Hodgkin lymphoma
by: Amandeep Aujla, et al.
Published: (2019)

Translocation ETS leukemia-acute myeloid leukemia 1 (TEL-AML1) gene fusion in childhood acute lymphoblastic leukemia
by: Sri Mulatsih, et al.
Published: (2009)

South African study of blast phase chronic myeloid leukaemia: A poor prognostic outlook
by: Katherine E. Hodkinson, et al.
Published: (2022)

The BCAT1 CXXC Motif Provides Protection against ROS in Acute Myeloid Leukaemia Cells
by: James Hillier, et al.
Published: (2022)

Role of long non-coding RNA HOTAIRM1 in the pathogenesis of paediatric acute myeloid leukaemia
by: Christine Wilson, et al.
Published: (2022)

Cachectic muscle wasting in acute myeloid leukaemia: a sleeping giant with dire clinical consequences
by: Dean G. Campelj, et al.
Published: (2022)

Cost-effectiveness analysis of escalating to natalizumab or switching among immunomodulators in relapsing-remitting multiple sclerosis in Italy
by: Gianluca Furneri, et al.
Published: (2019)

Cost-effectiveness analysis of brolucizumab versus aflibercept for the treatment of neovascular age-related macular degeneration (nAMD) in Italy
by: Nicola Ferrante, et al.
Published: (2022)

Cross-talk between Bcr-abl and the Thioredoxin System in Chronic Myeloid Leukaemia: Implications for CML Treatment
by: Erin Clapper, et al.
Published: (2020)

Clinical profile and outcomes of pediatric chronic myeloid leukaemia: A decade long single centre experience
by: Sreyashi Biswas, et al.
Published: (2024)

Assessment of clinical immunogenicity of inotuzumab ozogamicin in patients with non-Hodgkin lymphoma and acute lymphoblastic leukemia
by: Darshana Jani, et al.
Published: (2018)

Chidamide-based 3-drug combination regimen reverses molecular relapse post transplantation in AML1-ETO-positive acute myeloid leukemia
by: Yang Xi, et al.
Published: (2023)

First‐in‐human study of JNJ‐67571244, a CD33 × CD3 bispecific antibody, in relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome
by: Rupa Narayan, et al.
Published: (2024)